Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	97.76B
Revenue (ttm)	22.24B
Net Income (ttm)	4.62B
Shares Out	n/a
EPS (ttm)	3.66
PE Ratio	21.17
Forward PE	12.61
Dividend	2.41 (2.49%)
Ex-Dividend Date	Jun 13, 2025

Volume	5,270
Average Volume	3,373
Open	93.75
Previous Close	96.81
Day's Range	93.63 - 104.37
52-Week Range	49.43 - 78.63
Beta	0.34
RSI	50.06
Earnings Date	Apr 24, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD